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The EMBLEM™ entirely subcutaneous implantable cardioverter-defibrillator 
(S-ICD) system (Boston Scientific, Marlborough, Massachusetts, USA) was 
introduced as a new alternative to the conventional transvenous implantable 
cardioverter-defibrillator and has been expected to reduce device-related com-
plications, especially in young patients who require long-term lead placement. 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a well-known 
hereditary disease recognized as a cause of sudden cardiac death (SCD) in young 
adults. However, the precise clinical role of S-ICD in patients with ARVC remains 
to be defined because of the low QRS amplitude of subcutaneous electrocardiogram 
(S-ECG) followed by the high incidence of inappropriate shock (IAS) delivery due 
to oversensing. It is well known that the sensing of S-ICD is largely dependent on 
the QRS/T ratio of S-ECG. The decrease in the QRS amplitude is more likely to lead 
to oversensing such as T wave or myopotential oversensing. In patients with ARVC, 
the decrease in the QRS amplitude due to degeneration of the right ventricular 
myocardium progresses overtime. In this chapter, we would like to discuss the 
usefulness of S-ICD lead repositioning for young adult patients with ARVC based 
on our experience of patients with IAS.
Keywords: arrhythmogenic right ventricular cardiomyopathy, subcutaneous 
implantable cardioverter-defibrillator, inappropriate shock, lead repositioning
1. Introduction
The EMBLEM™ entirely subcutaneous implantable cardioverter-defibrillator 
(S-ICD) system (Boston Scientific, Marlborough, Massachusetts, USA) has been 
used as a new alternative to the conventional transvenous implantable cardioverter-
defibrillator (TV-ICD). Recently, the PREATORIAN study has shown that S-ICD 
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is as useful as TV-ICD for prevention of sudden cardiac death (SCD), mainly in 
patients with ischemic cardiomyopathy [1]. Furthermore, the UNTOUCHED study 
also demonstrated that the inappropriate shock (IAS) rate in S-ICD-implanted 
patients with left ventricular ejection fraction (LVEF) ≤ 35% for primary preven-
tion was non-inferior to that in transvenous ICD (TV-ICD)-implanted patients with 
similar programming as in the high-rate cutoff and long-delay therapy groups in the 
MADIT-RIT [2, 3].
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a well-known 
hereditary disease recognized as a cause of SCD in young adults [4]. However, the 
usefulness of S-ICD in patients with ARVC has not been established because of the 
low QRS amplitude of subcutaneous electrocardiogram (S-ECG) followed by the high 
incidence of IAS due to oversensing [5, 6]. We recently reported the usefulness of 
S-ICD lead repositioning to avoid IAS in patients with ARVC [7]. In this chapter, we 
will discuss the effectiveness of S-ICD lead repositioning for young adult patients with 
ARVC based on our clinical experience of patients with IAS.
2. Characteristics and problems of S-ICD sensing in patients with ARVC
The S-ICD uses a far-field bipolar electrocardiogram detected between two 
electrodes of S-ICD lead, or between one of the two electrodes and pulse-generator. 
This far-field bipolar electrocardiogram is called as subcutaneous electrocardio-
gram (S-ECG) and is used for detection and discrimination of tachyarrhythmias 
in current S-ICD system. The S-ECG shows lower QRS amplitude (0.3–4.0 mV) 
compared to intracardiac ECG, and longer QRS duration with many low frequency 
components. Since the basic morphology of S-ECG resembles a body surface ECG, 
it is easily affected by P wave and T wave, and is also easily affected by changes 
in the QRS complex to T wave (QRS/T) ratio during exercise. And S-ECG has a 
potential risk of myopotential interference (MPI) in certain periodic movements.
It has been suggested that fatal events occurring before overt structural myo-
cardial changes in patients with ARVC may be caused by a primarily electrical 
mechanism as a consequence of the cross talk of genetically defective desmosomal 
proteins with the voltage-gated sodium channel complex, leading to reduced 
sodium currents and arrhythmogenic mechanisms similar to those in Brugada 
syndrome [8]. It has also been known that the phenotype of fatal arrhythmias in 
patients with ARVC is age-dependent. Older patients with advanced disease more 
often experience re-entrant ventricular tachycardia (VT) around a myocardial 
fibro-fatty scar, whereas young patients commonly experience sudden onsets of 
ventricular fibrillation (VF) reflecting acute electrical instability in the early phases 
of the disease. Furthermore, S-ICD has been reported to have fewer lead-related 
complications than TV-ICD [1], and is also useful in younger patients who require 
long-term lead placement. Therefore, S-ICD is expected to prevent SCD, especially 
in young patients with ARVC.
However, the precise clinical role of S-ICD in patients with ARVC remains to be 
defined. One reason is that S-ICD does not have a function of anti-tachycardia pac-
ing that is expected to be highly effective in terminating scar-related re-entrant VT, 
which is often observed in patients with ARVC. Another reason is that morphologi-
cal changes in S-ECG with age may lead to cardiac oversensing and IAS delivery. In 
an Italian multicenter registry, which enrolled 44 young ARVC patients undergoing 
S-ICD implantation (mean age of 37 years; mean LVEF of 53%; primary prevention 
of 59%), 6 (14%) experienced 8 IAS deliveries, consisting of 4 cardiac oversensing 
and 4 non-cardiac oversensing [5]. Furthermore, in a transatlantic cohort study [6], 
which enrolled 29 young ARVC patients undergoing S-ICD implantation (mean age 
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of 34 years, mean LVEF of 56%, primary prevention of 59%), 6 (21%) experienced 
39 IAS deliveries due to oversensing. These studies indicate a high incidence of IAS 
delivery in S-ICD-implanted ARVC patients, leading to a potential limitation of 
S-ICD use in these patients.
3. Usefulness of lead repositioning of S-ICD in patients with ARVC
The conventional S-ICD system that we are using to date was developed and 
evaluated in the initial study [9]. In that study, the substernal lead was placed 
parallel to and 1 to 2 cm to the left of the sternal midline, and the pulse generator 
was placed over the sixth rib between the midaxillary line and the anterior axillary 
line. And the distal sensing electrode was positioned adjacent to the manubri-
osternal junction, and the proximal sensing electrode was positioned adjacent to 
the xiphoid process. The final position of S-ICD system was determined by the 
defibrillation threshold or the effectiveness of defibrillation. Notably, the position-
ing of S-ICD system was guided exclusively by anatomical landmarks, thus no 
fluoroscopy was required.
Recently, we reported the usefulness of S-ICD lead repositioning to avoid IAS in 
young patients with ARVC [7]. The most important benefit of S-ICD lead reposi-
tioning is an improved S-ECG sensing due to changes in QRS amplitude of S-ECG. 
The sensing of S-ICD is largely dependent on QRS/T ratio of S-ECG, which is 
vulnerable to changes caused by physical activities or the progression of underlying 
heart diseases. It has been well known that the decrease in QRS amplitude of S-ECG 
due to degeneration of the right ventricular myocardium progresses overtime in 
ARVC patients. Figure 1 shows ECG examples of a patient with ARVC in whom a 
decrease in QRS amplitude of surface ECG was confirmed over time. Of note, such 
changes in QRS amplitude were reflected more clearly in S-ECG compared with 
surface ECG. In such patients, S-ICD has a potential risk of IAS due to oversensing.
The SMART pass technology (SP) is a high-pass filter which enables to avoid 
sensing below 9 Hz and is expected to decrease IAS due to cardiac oversensing 
[10]. However, the decrease in QRS amplitude is more likely to lead to cardiac and 
Figure 1. 
Comparison of changes over time between body surface electrocardiogram and subcutaneous electrocardiogram 
(S-ECG). (a) Comparison of body surface ECG over time. The QRS amplitude decreases slightly over time 
in bipolar limb leads. (b) Comparison of S-ECG over time in the supine position. S-ECG was detected by 
alternate sensing vector with same detection sensitivity. The QRS amplitude of S-ECG decreases over time.
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Figure 2. 
Subcutaneous electrocardiogram (S-ECG) at inappropriate shock (IAS) deliveries. (a) S-ECG during the 
first IAS. The first IAS occurred when the patient was wiping his hair with a towel after bathing. The S-ICD 
was set to use the primary sensing vector at the time of IAS, and the Smart pass (SP) algorithm turned 
off automatically due to attenuated QRS amplitude. (b) S-ECG during the second IAS. The sensing vector 
was changed to alternate vector based on the results of exercise test. The IAS occurred when the patient was 
operating the smartphone in the left lateral position. Same as the first IAS, the SP algorithm turned off 
automatically due to attenuated QRS amplitude. (c) S-ECG during the third IAS. The IAS occurred when the 
patient was resting on the bed. The SP algorithm could not avoid IAS due to high-frequency MPI.
non-cardiac oversensing such as T wave or MPI, even if the SP is working properly. 
The SP can be set-up manually or automatically, but QRS amplitude of S-ECG is 
required to be higher than 0.5 mV. Furthermore, the SP is automatically terminated 
when there is no cardiac sensing for 10 seconds or when QRS amplitude of S-ECG 
decreases under 0.25 mV for 1.4 seconds or more. Therefore, there is a limitation to 
avoid IAS due to oversensing by SP alone in ARVC patients. For these reasons, lead 
repositioning of S-ICD can be a useful alternative to prevention of IAS in ARVC 
patients, even though the SP has been already activated.
4. Clinical practice of S-ICD lead repositioning in patients with ARVC
The potential efficacy of lead repositioning can be estimated by preoperative 
screening test. If two or more vectors do not pass the screening test, other sens-
ing vectors suitable for S-ICD sensing must be searched and lead repositioning or 
movement of the pulse generator, or both may be required.
Here is an example of S-ICD lead repositioning. The patient was a 17-year-old  
man who developed VF and was resuscitated by an automated external defibril-
lator. He was diagnosed with ARVC based on the task force criteria [11] and 
underwent S-ICD implantation for secondary prevention of SCD. Alternate 
vector was selected for S-ICD sensing by exercise tests after S-ICD implanta-
tion, and the SP algorithm was activated. Six months later, an emergency alert 
was transmitted via remote monitoring to notify the occurrence of the event 
just before the shock delivery. A close examination immediately after the alert 
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confirmed a decrease in QRS amplitude of S-ECG over time (Figure 1), and we 
changed sensing vector from the alternate vector to the primary vector. Seven 
months after the change of S-ICD sensing vector, the patient experienced a 
first IAS delivery. The S-ICD was set to use the primary sensing vector at the 
time of IAS, and the SP was turned off automatically due to attenuated QRS 
amplitude. S-ECG showed MPI that led to IAS delivery due to oversensing. After 
the changing the sensing vector to the alternate one, the patient had repeated 
IAS deliveries and eventually experienced IAS deliveries in all sensing vectors 
(Figure 2). Therefore, we performed an automated screening test (AST) on 
surface ECG again with a different electrode position. We performed an AST by 
moving the distal electrode approximately one intercostal space downward, and 
the proximal electrode was moved to the left, so that left ventricular electrocar-
diogram was more reflected on S-ECG. As a result, the QRS amplitude of S-ECG 
increased in 2 out of 3 sensing vectors and passed the AST. Thus, we performed 
repositioning of S-ICD lead under fluoroscopy (Figure 3). After repositioning 
of the S-ICD lead, the QRS amplitude of S-ECG increased and 2 (secondary and 
alternate sensing vectors) out of 3 vectors were suitable for S-ECG sensing, and 
there was no IAS for 15 months thereafter.
5. Limitation and future perspectives
As we described in the previous chapter, repositioning of the S-ICD lead to 
the lower left creates a new sensing vector that reflects more electrocardiograms 
of ventricular septum and left ventricle (Figure 4). Improved S-ECG sensing by 
the repositioning of the lead may be useful for patients not only with hereditary 
degenerative disease of the right ventricular myocardium such as ARVC, but 
also with acquired right ventricular myocardial damage such as right ventricular 
myocardial infarction. However, a concern in the method used in our case was that 
repositioned electrodes, especially the proximal electrode that was directly above or 
near the pectoralis major muscle, would be more vulnerable to MPI. Certainly, even 
after repositioning, slight MPI was observed in some sensing vectors, but it was 
possible to avoid MPI by selecting the optimal sensing vector based on the results of 
treadmill or other exercise test [12]. Furthermore, substernal tunneling method in 
Figure 3. 
Comparison of fluoroscopic images before and after lead repositioning and changes in S-ECG. The previously 
implanted S-ICD lead was placed at standard position based on the result of AST (a) This lead was moved 
to the lower left and QRS amplitude of S-ECG increased in 2 (secondary and alternate) out of 3 sensing 
vectors (b).
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which the distal electrode is placed on the sternum may also be useful for avoiding 
IAS due to MPI (Figures 5 and 6). More experiences and long-term follow-up may 
be necessary in order to establish the usefulness of the S-ICD lead repositioning in 
patients with ARVC. Further studies are clearly warranted.
Figure 4. 
Computed tomographic images after lead repositioning. It can be seen that the sensing vector between the 
repositioned proximal electrode and pulse generator is mediated by more left ventricular myocardium than 
the previously implanted proximal electrode position. The electrode position of previous implanted lead is 
illustrated based on previously captured CT image.
Figure 5. 
Method of substernal tunneling during lead repositioning. The tunneling method is shown in the order of  
(a to d) At first, the tip of the insertion tool was inserted diagonally to the right, and then gradually advance 
it toward cranial direction (a, b) After the tunneling tool was fully inserted, the lead was inserted into the 
introducer sheath as much as possible with two-incision technique (c) After peeling off the sheath, the lead was 
pulled back and placed at the pre-planned position (d).
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Figure 6. 
The 3D computed tomographic image in the left anterior oblique position after subcutaneous implantable 
cardioverter-defibrillator (S-ICD) implantation.
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